Literature DB >> 2559350

A pharmacological study of dopaminergic receptors in planaria.

G Venturini1, F Stocchi, V Margotta, S Ruggieri, D Bravi, P Bellantuono, G Palladini.   

Abstract

The dopaminergic receptors of planaria have been studied with pharmacological and biochemical criteria. Dopamine D1 selective agonists (CY 208243 (10 micrograms/ml) and SKF 38393 (10 micrograms/ml] induced in planaria typical screw-like hyperkinesias, that were inhibited by a D1 antagonist (SCH 23390 (10 micrograms/ml], but not by a D2 antagonist (sulpiride (1000 micrograms/ml]. Dopamine D2 selective agonists (PHNO (5 micrograms/ml), lisuride (5 micrograms/ml] on the contrary induced a typical "C" like curling, that was inhibited by pretreatment with D2 selective blocking agents, but not by D1 selective blocking agents. With agonists with a D1/D2 mixed action (apomorphine 60 micrograms/ml) or with amphetamine (100 micrograms/ml), the D1 type movements appeared to be more evident. Dopamine D1-selective agonists, mixed action agonists or D2-selective agonists, all induced a significant increase in levels of cAMP, that was prevented by pretreatment with the specific DA blocking agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559350     DOI: 10.1016/0028-3908(89)90013-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  15 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

2.  Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians.

Authors:  Robert B Raffa; Gregory W Stagliano; Ronald J Tallarida
Journal:  Eur J Pharmacol       Date:  2006-10-27       Impact factor: 4.432

3.  Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.

Authors:  Latha Ramakrishnan; Christina Amatya; Cassie J DeSaer; Zachary Dalhoff; Michael R Eggerichs
Journal:  Invert Neurosci       Date:  2014-01-09

4.  Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated Drosophila.

Authors:  C Yellman; H Tao; B He; J Hirsh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism.

Authors:  Suzan Owaisat; Robert B Raffa; Scott M Rawls
Journal:  Neurosci Lett       Date:  2012-08-03       Impact factor: 3.046

6.  Nicotine behavioral pharmacology: clues from planarians.

Authors:  Scott M Rawls; Tanvi Patil; Christopher S Tallarida; Steven Baron; Myongji Kim; Kevin Song; Sara Ward; Robert B Raffa
Journal:  Drug Alcohol Depend       Date:  2011-05-06       Impact factor: 4.492

7.  First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians.

Authors:  Scott M Rawls; Tavni Patil; Ekaternia Yuvasheva; Robert B Raffa
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

8.  The kappa-opioid receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN 52212-2), abstinence-induced withdrawal in planarians: an instance of 'pharmacologic congruence'.

Authors:  Robert B Raffa; Gregory W Stagliano; Geoffrey Ross; Jenay A Powell; Austin G Phillips; Zhe Ding; Scott M Rawls
Journal:  Brain Res       Date:  2007-12-08       Impact factor: 3.252

9.  Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists.

Authors:  Robert B Raffa; Federica Cavallo; Anna Capasso
Journal:  Eur J Pharmacol       Date:  2007-02-16       Impact factor: 4.432

10.  An exploratory evaluation of tyrosine hydroxylase inhibition in planaria as a model for parkinsonism.

Authors:  David Prokai; Thinh Nguyen; Kurt Kamrowski; Ashwin Chandra; Tatjana Talamantes; Lewis R Baxter; Laszlo Prokai
Journal:  Int J Mol Sci       Date:  2013-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.